Abbott India Limited (ABBOTINDIA) Operating Income 2023–TTM

Name: Abbott India Limited (ABBOTINDIA) operating income history 2023-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-10-27

Abbott India Limited annual operating income for fiscal TTM was ₹18.9 billion, an increase of 3.7% from ₹18.2 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

ABBOTINDIA Annual Operating Income

Operating Income (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Operating Income (EBIT)	₹18.9B	₹18.2B	₹16.4B	₹14.1B	₹11.5B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABBOTINDIA Quarterly Operating Income

Operating Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Operating Income (EBIT)	₹5.0B	₹4.6B	₹4.4B	₹4.8B	₹4.3B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

LUPIN Operating Income — Lupin Limited
4506 Operating Income — Sumitomo Pharma Co., Ltd.
GLENMARK Operating Income — Glenmark Pharmaceuticals Limited
ALKEM Operating Income — Alkem Laboratories Limited
GLAND Operating Income — Gland Pharma Limited
IPCALAB Operating Income — Ipca Laboratories Limited

More ABBOTINDIA metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All ABBOTINDIA financial statements → Interactive ABBOTINDIA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.